Recruiting

NCT Number: NCT06259162

LAG3 Expression in Triple Negative Breast Cancer

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Triple Negative Breast Cancer Breast Diseases Breast Neoplasms Immune Checkpoint Inhibitor Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases Triple Negative Breast Neoplasms

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Ji-Yeon Kim

Seoul, 06351, South Korea

Location status: Recruiting

Location contact

Ji-Yeon Kim

CONTACT

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Planned neoadjuvant chemotherapy
Triple negative breast cancer

Exclusion criteria

HER2-positive breast cancer
Hormone receptor positive breast cancer

Treatment and study plan

LAG-3 expression / immune checkpoint protein expression

Procedure

Evaluate the tissue and blood before and after chemotherapy

Primary outcomes

LAG-3 expression/immune checkpoint preotein expression

Time frame: Before chemotherapy, 1 weeks & 3 weeks after chemotherapy, curative surgery

Relationship neoadjuvant chemotherapy plus immune checkpoint inhibitor

Study contacts

Contact information is provided by the study sponsor or research team.

Ji-Yeon Kim

CONTACT

[email protected]

82-2-3410-3459

Mee Ryung Hong

CONTACT

[email protected]

82-2-2148-7147

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

The Evaluation the Relationship Between LAG-3 Expression / Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer

Important dates

Study start: 2022
Primary completion: 2025
Study completion: 2027
First posted: Feb 14, 2024
Registry last updated: Feb 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting